ISLET TRANSPLANTATION IN TYPE I DIABETIC REICIPIENTS OF RENAL ALLOGRAFT USING TH

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在1型糖尿病中，胰腺中制造胰岛素的胰岛细胞被认为在免疫反应中被摧毁。胰岛细胞移植是一种实验疗法，目前正在难以控制的1型糖尿病患者身上进行测试，这些人在肾移植后已经处于免疫抑制状态。在这个方案中，胰岛细胞从捐赠者身上采集并培养以供输注。这是一项开放标签的可行性研究，其主要目的是测试在加拿大埃德蒙顿看到的胰岛移植结果是否可以在免疫抑制的肾移植患者身上重复，并测试这一研究程序的安全性。这项研究将包括筛查评估、治疗阶段和持续约12个月的后续阶段。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In Type 1 diabetes, islet cells in the pancreas, which make insulin, are thought to be destroyed in an immune response. Islet cell transplantation is a procedure that is being tested as an experimental therapy in individuals with difficult to control Type 1 diabetes who are already on immunosuppression following a kidney transplant. In this protocol, islet cells are harvested from a donor and cultured for infusion. This is an open label, feasibility study whose primary purpose is to test whether islet transplantation results seen in Edmonton, Canada can be repeated in immunosuppressed kidney transplant patients and to test the safety of this investigational procedure. The study will consist of a screening evaluation, the treatment phase, and a follow-up phase lasting approximately 12 months.